

# Chlamydia and Gonorrhea: Screening

September 14, 2021

*Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.*

## Recommendation Summary

Population	Recommendation	Grade
Sexually active women, including pregnant persons	The USPSTF recommends screening for chlamydia in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection.	<b>B</b>
Sexually active women, including pregnant persons	The USPSTF recommends screening for gonorrhea in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection.	<b>B</b>
Sexually active men	The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men.	<b>I</b>

## Clinician Summary

<b>What does the USPSTF recommend?</b>	<p><b>For sexually active women, including pregnant persons:</b></p> <p><b>Screen</b> for chlamydia if they are</p> <ul style="list-style-type: none"> <li>• 24 years or younger</li> <li>• 25 years or older and at increased risk for infection</li> </ul> <p><b>Grade: B</b></p> <p><b>Screen</b> for gonorrhea if they are</p> <ul style="list-style-type: none"> <li>• 24 years or younger</li> <li>• 25 years or older and at increased risk for infection</li> </ul> <p><b>Grade: B</b></p> <p>See below for how to implement this recommendation.</p> <p><b>For sexually active men:</b></p> <ul style="list-style-type: none"> <li>• The USPSTF found that the evidence is insufficient to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men. More research is needed.</li> </ul> <p><b>I statement</b></p>
<b>To whom does this recommendation apply?</b>	Sexually active adolescents and adults, including pregnant persons, without signs and symptoms of chlamydia or gonorrhea infection.
<b>What's new?</b>	This recommendation is consistent with the 2014 USPSTF recommendation.

<p><b>How to implement this recommendation?</b></p>	<p><b>1. Assess Risk.</b></p> <ul style="list-style-type: none"> <li>◦ Women aged 15 to 24 years have the highest infection rates.</li> <li>◦ Women 25 years or older are at increased risk if they have           <ul style="list-style-type: none"> <li>▪ A previous or coexisting STI</li> <li>▪ A new or more than 1 sex partner</li> <li>▪ A sex partner having sex with other partners at the same time</li> <li>▪ A sex partner with an STI</li> <li>▪ Inconsistent condom use when not in a mutually monogamous relationship</li> <li>▪ A history of exchanging sex for money or drugs</li> <li>▪ A history of incarceration</li> </ul> </li> </ul> <p>Clinicians should consider the communities they serve and may want to consult local public health authorities for information about local epidemiology and guidance on determining who is at increased risk.</p> <p><b>2. Screen for chlamydia and gonorrhea in sexually active women:</b></p> <ul style="list-style-type: none"> <li>◦ 24 years or younger</li> <li>◦ 25 years or older and at increased risk for infection</li> </ul> <p>Screen for chlamydia and gonorrhea using a NAAT. NAATs can test for infection at urogenital and extragenital sites, including urine, endocervical, vaginal, male urethral, rectal, and pharyngeal. Both chlamydia and gonorrhea can be tested for at the same time with the same specimen.</p>
<p><b>What are other relevant USPSTF recommendations?</b></p>	<p>The USPSTF has issued recommendations on screening for other STIs, including hepatitis B, hepatitis C, genital herpes, HIV, and syphilis. The USPSTF has also issued recommendations on behavioral counseling for all sexually active adolescents and for adults at increased risk for STIs. These recommendations are available at <a href="http://www.uspreventiveservicestaskforce.org">www.uspreventiveservicestaskforce.org</a>.</p>
<p><b>Where to read the full recommendation statement?</b></p>	<p>Visit the USPSTF website to read the full recommendation statement. This includes more details on the rationale of the recommendation, including benefits and harms; supporting evidence; and recommendations of others.</p>

*The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision making to the specific patient or situation.*

Abbreviations: NAAT, nucleic acid amplification test; STI, sexually transmitted infection; USPSTF, US Preventive Services Task Force.

[View the Clinician Summary in PDF](#)

## Additional Information

[Final Evidence Review \(September 14, 2021\)](#)

[Evidence Summary \(September 14, 2021\)](#)

[Final Research Plan \(May 02, 2019\)](#)

# Recommendation Information

Table of Contents	PDF Version and JAMA Link	Archived Versions
Importance	View the Recommendation in PDF Format	(September 2014)
USPSTF Assessment of Magnitude of Net Benefit	To read the recommendation statement in <i>JAMA</i> , select here.	(June 2007)
Practice Considerations		(May 2005)
Update of Previous USPSTF Recommendation	To read the evidence summary in <i>JAMA</i> , select here.	(January 2001)
Supporting Evidence		(January 1996)
Research Needs and Gaps		(January 1996)
Recommendations of Others		
Members of the US Preventive Services		
Copyright and Source Information		
References		

## Full Recommendation:

Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

### Importance

Chlamydia and gonorrhea are among the most common sexually transmitted infections (STIs) in the US.<sup>1</sup> Approximately 1.8 million cases of chlamydia and more than 600,000 cases of gonorrhea were reported to the Centers for Disease Control and Prevention (CDC) in 2019. The rate of chlamydia infection among women (698.9 cases per 100,000 women) was nearly double the rate among men (399.9 cases per 100,000 men). Gonorrhea infection was more prevalent in men (224.4 cases per 100,000 men) than in women (152.6 cases per 100,000 women). Infection rates are highest among adolescents and young adults of both sexes. In 2019 almost two-thirds (61.0%) of all reported chlamydia infections, and in 2018 more than half (54.1%) of new gonococcal infections, were among persons aged 15 to 24 years.<sup>1,2</sup>

Chlamydial and gonococcal infections in women are usually asymptomatic and may lead to pelvic inflammatory disease (PID) and its associated complications, such as ectopic pregnancy, infertility, and chronic pelvic pain.<sup>3-5</sup> Newborns of pregnant persons with untreated infection may develop neonatal chlamydial pneumonia or gonococcal or chlamydial ophthalmia.<sup>6,7</sup> Infection in men may lead to urethritis and epididymitis.<sup>8-11</sup> Men are often asymptomatic; however, gonorrhea is more likely than chlamydia to cause symptoms in men than in women.<sup>12</sup> Both types of infection can increase risk of acquiring or transmitting HIV.<sup>13,14</sup>

### USPSTF Assessment of Magnitude of Net Benefit

The US Preventive Services Task Force (USPSTF) concludes with moderate certainty that screening for chlamydia in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection has **moderate net benefit**.

The USPSTF concludes with moderate certainty that screening for gonorrhea in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection has **moderate net benefit**.

The USPSTF concludes that the current **evidence is insufficient** to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men.

See the Table for more information on the USPSTF recommendation rationale and assessment. For more details on the methods the USPSTF uses to determine the net benefit, see the USPSTF Procedure Manual.<sup>15</sup>

## Practice Considerations

# Patient Population Under Consideration

This recommendation applies to asymptomatic, sexually active adolescents and adults, including pregnant persons.

In this recommendation statement, the recommendations are stratified by “men” and “women,” although the net benefit estimates are driven by biological sex (ie, male/female) rather than gender identity. Persons should consider their sex at birth and current anatomy (especially presence of a cervix/vagina) and consult with their own clinician, if necessary, to determine which recommendation best applies to them.

## Assessment of Risk

Age is a strong predictor of risk for chlamydial and gonococcal infections, with the highest infection rates in women occurring during ages 15 to 24 years.<sup>1</sup> Women 25 years or older are at increased risk if they have a new sex partner, more than 1 sex partner, a sex partner with concurrent partners, or a sex partner who has an STI; practice inconsistent condom use when not in a mutually monogamous relationship; or have a previous or coexisting STI. Exchanging sex for money or drugs and history of incarceration also are associated with increased risk.<sup>16</sup> Clinicians should consider the communities they serve and may want to consult local public health authorities for information about local epidemiology and guidance on determining who is at increased risk.

## Screening Tests

Nucleic acid amplification tests (NAATs) for *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infections are usually used for screening because their sensitivity and specificity are high for detecting these infections.<sup>17</sup> The US Food and Drug Administration approves NAATs for use on urogenital and extragenital sites, including urine, endocervical, vaginal, male urethral, rectal, and pharyngeal specimens.<sup>17,18</sup> Urine testing with NAATs is at least as sensitive as testing with endocervical specimens, clinician- or self-collected vaginal specimens, or urethral specimens in clinical settings. The same specimen can be used to test for chlamydia and gonorrhea.<sup>19</sup>

## Screening Intervals

In the absence of studies on screening intervals, a reasonable approach would be to screen patients whose sexual history reveals new or persistent risk factors since the last negative test result.

## Treatment or Interventions

Chlamydial and gonococcal infections respond to treatment with antibiotics. Because treatment varies depending on the individual patient, and antibiotic resistance for gonorrhea is increasing, clinicians are encouraged to consult the most up-to-date guidance on treatment from the CDC.<sup>16,20</sup>

## Implementation

Although the prevalences of chlamydia and gonorrhea differ, the risk factors for infection overlap, and the USPSTF recommends screening for both simultaneously. The USPSTF did not review evidence on screening for chlamydia and gonorrhea in persons living with HIV or taking HIV preexposure prophylaxis. The CDC provides recommendations for these and other specific groups.

The CDC also describes ways to increase adherence to treatment and interventions to decrease the likelihood of reinfection.<sup>16,20,21</sup>

## Other Related USPSTF Recommendations

The USPSTF has issued recommendations on screening for other STIs, including hepatitis B,<sup>22,23</sup> hepatitis C,<sup>24</sup> genital herpes,<sup>25</sup> HIV,<sup>26,27</sup> and syphilis.<sup>28,29</sup> The USPSTF has also issued recommendations on behavioral counseling for all sexually active adolescents and for adults who are at increased risk for STIs.<sup>30</sup>

## Additional Tools and Resources

The CDC provides more information about STIs, including chlamydia and gonorrhea, at <https://www.cdc.gov/std/default.htm>, as well as guidance for clinicians on providing quality STI clinical services, at <https://www.cdc.gov/mmwr/volumes/68/rr/rr6805a1.htm>.

The National Academies of Sciences, Engineering, and Medicine provides a comprehensive systems-based approach for prevention and control of STIs at <https://www.nap.edu/catalog/25955/sexually-transmitted-infections-adopting-a-sexual-health-paradigm>.

The Community Preventive Services Task Force has issued several recommendations on the prevention of HIV/AIDS, other STIs, and teen pregnancy. The Community Guide discusses interventions that have been efficacious in school settings, and for men who have sex with men, at <https://www.thecommunityguide.org/topic/hiv-stis-and-teen-pregnancy>.

The Public Health Agency of Canada guidelines on STIs are available at <https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/sexually-transmitted-infections.html>.

## Suggestions for Practice Regarding the I Statement

### Potential Preventable Burden

Chlamydial and gonococcal infections are often asymptomatic in men but may result in urethritis, epididymitis, and proctitis. Uncommon complications include reactive arthritis (chlamydia) and disseminated gonococcal infection.<sup>16</sup> Urogenital positivity among men who have sex with men was 6% for chlamydia and 7% for gonorrhea across 11 Sexually Transmitted Disease Surveillance Network jurisdictions in 2019.<sup>1</sup> Infections at extragenital sites (such as the pharynx and rectum) are typically asymptomatic. Chlamydial and gonococcal infections may increase risk of acquiring or transmitting HIV.<sup>13,14</sup>

### Potential Harms

Potential harms of screening for chlamydia and gonorrhea include false-positive or false-negative results as well as labeling and anxiety associated with positive results.

### Current Practice

A review of health care claims of 4296 male and female patients presenting for general medical or gynecologic examinations from 2000 to 2003 found that a large proportion of patients with high-risk sexual behaviors did not receive STI or HIV testing during their visit.<sup>31</sup> According to a review of diagnostic billing codes for 1074 patients with high-risk sexual behaviors, men were significantly less likely than women to be tested for chlamydia (20.7% vs 56.9%) and gonorrhea (20.7% vs 50.9%), although they were more likely to be tested for HIV (79.3% vs 38.8%) and syphilis (39.1% vs 27.6%).<sup>31</sup>

Update of Previous USPSTF Recommendation

This recommendation updates the USPSTF's 2014 recommendation on screening for chlamydia and gonorrhea.

In 2014, the USPSTF recommended screening for chlamydia in sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection. It also recommended screening for gonorrhea in sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection. Both recommendations included pregnant persons. The USPSTF found insufficient evidence to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men.

## Supporting Evidence

## Scope of Review

The USPSTF commissioned a systematic review<sup>19,32</sup> to update its recommendation on screening for chlamydia and gonorrhea. The review evaluated the benefits and harms of screening for chlamydia and gonorrhea in all sexually active adolescents and adults, including pregnant persons. Key differences between the current review and the prior review are that the current review combined all populations, including pregnant persons, into a single analytic framework; evaluated the accuracy of risk stratification and screening strategies for identifying persons at increased risk; and focused evaluation of diagnostic accuracy on anatomical site-specific testing.<sup>19,32,33</sup> Because the USPSTF had previously determined that treatments for these infections are effective and well established, this review did not include a review of treatments.<sup>19,32</sup>

## Accuracy of Screening Tests and Risk Assessment

The USPSTF found convincing evidence that clinicians could identify sexually active women at increased risk for chlamydial and gonococcal infections. It found adequate evidence that clinicians could identify sexually active men at increased risk for chlamydial and gonococcal infections. Seven new fair-quality studies with more than 93,000 participants were included in the analysis.<sup>34-39</sup> In asymptomatic individuals, 3 studies with 71,636 participants that used a risk score to identify persons with chlamydial or gonococcal infections reported an area under the curve of 0.64 to 0.73.<sup>34-36</sup> One study showed that age (younger than 22 years) alone had accuracy similar to that for the use of more extensive risk criteria.<sup>39</sup>

The USPSTF found convincing evidence that available screening tests can accurately diagnose chlamydial and gonococcal infections in both women and men. Nine fair-quality studies in more than 16,000 participants indicated that screening for chlamydia and gonorrhea with NAATs is highly accurate for specimens from various anatomical sites and different collection methods for women and men.<sup>40-48</sup> Sensitivity of NAAT specimens collected from urogenital sites for detecting chlamydia and gonorrhea in women ranged from 72% to 100%, excluding 1 outlier study. Sensitivity among collection methods, including vaginal clinician- or self-collection or urine collection, varied little. NAATs for chlamydia and gonorrhea screening in men was highly accurate, with sensitivities ranging from 89% to 100% for urethral, meatal, and urine testing. NAATs were also highly sensitive for detecting rectal and pharyngeal gonorrhea and rectal chlamydia in men (89% to 93%); they had moderate sensitivity (69%) for detecting pharyngeal chlamydia in men. Specificity for several sites was high, ranging from 90% to 100% for both infections in men and women. Specificity was not reported for gonorrhea in women at the urethral site and in men at the urethral, rectal, or pharyngeal sites.<sup>19</sup>

## Benefits of Early Detection and Treatment

The USPSTF reviewed 4 trials and concluded that screening was associated with reduced risk of PID vs no screening.<sup>49-52</sup> One recent large, good-quality trial of men and women ( $n = 63,338$ ) in primary care clinics found that screening for chlamydia was associated with a reduction in risk of hospital-diagnosed PID compared with usual care (relative risk, 0.6 [95% CI, 0.4-1.0]), but the absolute difference was small (0.24% vs 0.38%). No differences were seen in rates of PID or epididymitis in clinics.<sup>52</sup> No studies reported the association between screening and disease acquisition or transmission or between screening and clinical outcomes other than PID or epididymitis.<sup>19</sup>

The USPSTF previously found fair-quality evidence that treatment of chlamydial infection during pregnancy is associated with improved outcomes for infants and mothers.<sup>53,54</sup> The USPSTF reviewed large cohort studies of screening at the first prenatal visit in pregnant women (with a total of 11,544 participants) at increased risk for infection. These studies found that treatment of

chlamydial infection was associated with significantly lower rates of preterm delivery, early rupture of membranes, and infants with low birth weight compared with no treatment or treatment failure.<sup>53,54</sup> No subsequent studies met inclusion criteria for the current USPSTF review.<sup>19,32</sup>

The USPSTF found little direct evidence on the effectiveness of screening for chlamydia in men or low-risk women in reducing infection complications or disease transmission or acquisition. It found that the overall prevalence of chlamydial infection in the general population varies widely depending on age and other risk factors. Chlamydial infection may cause urethritis and epididymitis in men, but serious complications are not common. Screening and treating young men at increased risk may reduce the incidence of chlamydial infection; however, the USPSTF found very limited published randomized trials or observational studies of the effect of routine screening in men or comparison with the strategy of screening women and treating their male partners.<sup>19,32</sup> The USPSTF found no studies on the benefits of screening women, including pregnant women, who are not at increased risk for infection.<sup>19,32</sup>

The USPSTF found no studies that directly evaluated the effectiveness of screening for gonorrhea in its current or previous reviews.<sup>19,32,33</sup> It previously found indirect evidence of the benefits of early detection and treatment in women at increased risk based on the substantial prevalence of asymptomatic infection, the availability of accurate screening tests and effective treatments, and the high morbidity associated with untreated infection in women.<sup>55</sup> Gonococcal infections in women are frequently asymptomatic but represent an important reservoir of infection that could lead to reproductive complications and life-threatening conditions.

Based on indirect evidence, early detection and treatment of gonorrhea in pregnant women at increased risk for infection may decrease morbidity from infection-related obstetric complications. In women not at increased risk for gonorrhea, there is a low prevalence of infection, and universal ocular prophylaxis in newborns is effective and well established. Accordingly, the USPSTF concluded that the net benefit of screening for gonorrhea in pregnant women who are not at increased risk for infection is small.

The USPSTF found little evidence on the effectiveness of screening for gonorrhea in men or low-risk women. Prevalence in these groups is low.<sup>1</sup> Moreover, the majority of genital gonococcal infections in men are symptomatic, which can result in more timely clinical presentation and lead to diagnosis and treatment that prevents serious complications.

The USPSTF found no studies comparing the effectiveness of cotesting for concurrent STIs or using different screening intervals.<sup>19,32</sup>

## Harms of Screening and Treatment

The USPSTF reviewed several studies, including 4 recent studies ( $n = 5666$ ), assessing harms of site-specific chlamydia and gonorrhea testing as well as harms of collection methods in women. The false-positive, false-negative, false alarm, and false reassurance rates varied by anatomical site but were overall generally low across all NAATs and specimen types.<sup>19,32</sup>

No studies of psychosocial harms, such as anxiety, related to testing met inclusion criteria for this or prior reviews.<sup>19,32</sup>

## Response to Public Comment

A draft version of this recommendation statement was posted for public comment on the USPSTF website from March 2 through March 29, 2021. Several comments expressed concern that the USPSTF found insufficient evidence to screen men and did not provide separate recommendations for specific high-risk populations. The USPSTF did not identify enough evidence to support that screening men for chlamydia and gonorrhea improves health outcomes by reducing infection complications or disease transmission or acquisition, including HIV. In the Research Needs and Gaps section, the USPSTF calls for more research on screening in men and other groups such as men who have sex with men; the lesbian, gay, bisexual, transgender, queer/questioning (LGBTQ+) community; and racial and ethnic minorities. The USPSTF also clarified to whom the recommendation applies regarding sex and gender in the Practice Considerations section. Some comments requested that universal, rather than risk-based, screening be recommended for women 25 years or older. Based on available disease prevalence data and accuracy of risk assessment tools, the USPSTF found that younger age was a strong predictor of disease risk, which was clarified in the Practice Considerations section. Comments also asked for clarification on screening intervals. Given the lack of available evidence on optimal screening frequency, the USPSTF provides a reasonable approach for rescreening in the Practice Considerations section.

# How Does Evidence Fit With Biological Understanding?

Chlamydial and gonococcal infections are often asymptomatic in women. Untreated infections may progress to PID-related complications such as chronic pelvic pain, ectopic pregnancy, or infertility. Infections may also be transmitted to sex partners and newborn children. Accurate screening tests and effective antibiotic treatments are available for chlamydia and gonorrhea.

In men, gonococcal infections are more commonly symptomatic compared with women. Serious complications from infection are less common in men.

## Research Needs and Gaps

Studies on assessing risk and for whom screening may be most effective are a high priority.

- Studies evaluating the effectiveness of screening asymptomatic men to reduce infection complications and transmission or acquisition of either disease or HIV are needed.
- Studies are needed to better understand the benefits and harms of screening specific populations at risk such as men who have sex with men, members of the LGBTQ+ community, and persons with nonbinary gender identity.
- Prevalence of chlamydia and gonorrhea is high among American Indian/Alaska Native, Black, Hispanic/Latino, and Native Hawaiian/Pacific Islander persons. Studies providing information on differential access and effective prevention strategies for these populations may help reduce racial and ethnic disparities.
- Studies with direct evidence on the effectiveness of screening pregnant persons, testing extragenital sites, cotesting for concurrent STIs, and screening intervals would help provide more information for best practices.

## Recommendations of Others

The CDC recommends annual chlamydia and gonorrhea testing in all sexually active women younger than 25 years and in older women at increased risk of infection (ie, those who have a new or multiple sex partners or a sex partner who has an STI). It also recommends screening for both infections in pregnant women younger than 25 years and in older pregnant women at increased risk for infection during their first prenatal visit and again during their third trimester if risk remains high.<sup>16</sup>

The CDC recommends that clinicians consider screening for chlamydia in sexually active young men in high-prevalence areas and populations. It recommends annual screening for chlamydia and gonorrhea at appropriate anatomical sites of exposure in men who have sex with men, with more frequent screening if risk behaviors persist or if they or their sex partners have multiple partners. The CDC recommends screening transgender individuals on the basis of their sexual practices and anatomy. Because of high rates of STIs in persons entering correctional facilities, the CDC recommends chlamydia and gonorrhea screening at intake in correctional facilities in women 35 years or younger and in men younger than 30 years. Because of the high likelihood of reinfection, the CDC recommends retesting all patients diagnosed with chlamydial or gonococcal infections 3 months after treatment, regardless of whether they believe their partners have been treated.<sup>16</sup>

The American College of Obstetricians and Gynecologists follows the CDC's recommendations for annual chlamydia and gonorrhea screening in all sexually active women younger than 25 years and in older women with risk factors. However, it recommends that all pregnant women be tested for chlamydia early in pregnancy, with a repeat test in the third trimester for women with risk factors. It recommends testing for gonorrhea in pregnant women 25 years or younger or for those living in an area where gonorrhea is common.<sup>56,57</sup>

The American Academy of Family Physicians follows the 2014 USPSTF chlamydia and gonorrhea screening recommendations.<sup>58</sup> The American Academy of Pediatrics recommendations align with the CDC guidelines.<sup>59</sup>

The US Preventive Services Task Force members include the following individuals: Karina W. Davidson, PhD, MASC (Feinstein Institutes for Medical Research at Northwell Health, Manhasset, New York); Michael J. Barry, MD (Harvard Medical School, Boston, Massachusetts); Carol M. Mangione, MD, MSPH (University of California, Los Angeles); Michael Cabana, MD, MA, MPH (Albert Einstein College of Medicine, New York, New York); Aaron B. Caughey, MD, PhD (Oregon Health & Science University, Portland); Esa M. Davis, MD, MPH (University of Pittsburgh, Pittsburgh); Katrina E. Donahue, MD, MPH (University of North Carolina at Chapel Hill); Chyke A. Doubeni, MD, MPH (Mayo Clinic, Rochester, Minnesota); Martha Kubik, PhD, RN (George Mason University, Fairfax, Virginia); Li Li, MD, PhD, MPH (University of Virginia, Charlottesville); Gbenga Ogedegbe, MD, MPH (New York University, New York, New York); Lori Pbert, PhD (University of Massachusetts Medical School, Worcester); Michael Silverstein, MD, MPH (Boston University, Boston, Massachusetts); Melissa A. Simon, MD, MPH (Northwestern University, Chicago, Illinois); James Stevermer, MD, MSPH (University of Missouri, Columbia); Chien-Wen Tseng, MD, MPH, MSEE (University of Hawaii, Honolulu); John B. Wong, MD (Tufts University School of Medicine, Boston, Massachusetts).

#### Copyright and Source Information

**Conflict of Interest Disclosures:** Authors followed the policy regarding conflicts of interest described at <https://uspreventiveservicestaskforce.org/uspstf/about-uspstf/conflict-interest-disclosures>. All members of the USPSTF receive travel reimbursement and an honorarium for participating in USPSTF meetings.

**Funding/Support:** The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the US Preventive Services Task Force (USPSTF).

**Role of the Funder/Sponsor:** AHRQ staff assisted in the following: development and review of the research plan, commission of the systematic evidence review from an Evidence-based Practice Center, coordination of expert review and public comment of the draft evidence report and draft recommendation statement, and the writing and preparation of the final recommendation statement and its submission for publication. AHRQ staff had no role in the approval of the final recommendation statement or the decision to submit for publication.

**Disclaimer:** Recommendations made by the USPSTF are independent of the US government. They should not be construed as an official position of AHRQ or the US Department of Health and Human Services.

**Additional Information:** The US Preventive Services Task Force USPSTF makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms. It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment. The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision-making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms. Published by *JAMA®—Journal of the American Medical Association* under arrangement with the Agency for Healthcare Research and Quality (AHRQ). ©2021 AMA and United States Government, as represented by the Secretary of the Department of Health and Human Services (HHS), by assignment from the members of the United States Preventive Services Task Force (USPSTF). All rights reserved.

**Copyright Notice:** USPSTF recommendations are based on a rigorous review of existing peer-reviewed evidence and are intended to help primary care clinicians and patients decide together whether a preventive service is right for a patient's needs. To encourage widespread discussion, consideration, adoption, and implementation of USPSTF recommendations, AHRQ permits members of the public to reproduce, redistribute, publicly display, and incorporate USPSTF work into other materials provided that it is reproduced without any changes to the work of portions thereof, except as permitted as fair use under the US Copyright Act.

AHRQ and the US Department of Health and Human Services cannot endorse, or appear to endorse, derivative or excerpted materials, and they cannot be held liable for the content or use of adapted products that are incorporated on other Web sites. Any adaptations of these electronic documents and resources must include a disclaimer to this effect. Advertising or implied endorsement for any commercial products or services is strictly prohibited.

This work may not be reproduced, reprinted, or redistributed for a fee, nor may the work be sold for profit or incorporated into a profit-making venture without the express written permission of AHRQ. This work is subject to the restrictions of Section 1140 of the Social Security Act, 42 U.S.C. §320b-10. When parts of a recommendation statement are used or quoted, the USPSTF Web page should be cited as the source.

## References

1. Sexually transmitted disease surveillance 2019. Centers for Disease Control and Prevention. Reviewed 2021. Accessed July 28, 2021. <https://www.cdc.gov/std/statistics/2019/default.htm>
2. Kreisel KM, Spicknall IH, Gargano JW, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2018. *Sex Transm Dis.* 2021;48(4):208-214. Medline:33492089 doi:10.1097/OLQ.00000000000001355
3. Brunham RC, Gottlieb SL, Paavonen J. Pelvic inflammatory disease. *N Engl J Med.* 2015;372(21):2039-2048. Medline:25992748 doi:10.1056/NEJMra1411426
4. Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted diseases: the case for screening. *Prev Med.* 2003;36(4):502-509. Medline:12649059 doi:10.1016/S0091-7435(02)00058-0
5. Reekie J, Donovan B, Guy R, et al; Chlamydia and Reproductive Health Outcome Investigators; Chlamydia and Reproductive Health Outcome Investigators. Risk of pelvic inflammatory disease in relation to chlamydia and gonorrhea testing, repeat testing, and positivity: a population-based cohort study. *Clin Infect Dis.* 2018;66(3):437-443. Medline:29136127 doi:10.1093/cid/cix769
6. American Academy of Pediatrics. Prevention of neonatal ophthalmia. In: Kimberlin DW, Brady MT, Jackson MA, eds. *Red Book: 2018 Report of the Committee on Infectious Diseases.* 31st ed. American Academy of Pediatrics; 2018:1047-1102.
7. Hammerschlag MR. Chlamydial and gonococcal infections in infants and children. *Clin Infect Dis.* 2011;53(suppl 3):S99-S102. Medline:22080275 doi:10.1093/cid/cir699
8. Stamm WE. *Chlamydia trachomatis* infections of the adult. In: Holmes K, ed. *Sexually Transmitted Disease.* 4th ed. McGraw-Hill; 2008.
9. Berger RE, Alexander ER, Monda GD, Ansell J, McCormick G, Holmes KK. *Chlamydia trachomatis* as a cause of acute "idiopathic" epididymitis. *N Engl J Med.* 1978;298(6):301-304. Medline:622087 doi:10.1056/NEJM197802092980603
10. Jacobs NF, Kraus SJ. Gonococcal and nongonococcal urethritis in men: clinical and laboratory differentiation. *Ann Intern Med.* 1975;82(1):7-12. Medline:67816 doi:10.7326/0003-4819-82-1-7
11. McConaghy JR, Panchal B. Epididymitis: an overview. *Am Fam Physician.* 2016;94(9):723-726. Medline:27929243
12. Korenromp EL, Sudaryo MK, de Vlas SJ, et al. What proportion of episodes of gonorrhoea and chlamydia becomes symptomatic? *Int J STD AIDS.* 2002;13(2):91-101. Medline:11839163 doi:10.1258/0956462021924712
13. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. *Sex Transm Infect.* 1999;75(1):3-17. Medline:10448335 doi:10.1136/sti.75.1.3

14. Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. *Sex Transm Infect*. 2011;87(3):183-190. Medline:21330572 doi:10.1136/sti.2010.047514
15. Procedure Manual. US Preventive Services Task Force. Published May 2021. Accessed July 28, 2021. <https://uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/procedure-manual>
16. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. *MMWR Recomm Rep*. 2021;70(4):1-187. Medline:34292926 doi:10.15585/mmwr.rr7004a1
17. Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*—2014. *MMWR Recomm Rep*. 2014;63(RR-02):1-19. Medline:24622331
18. FDA clears first diagnostic tests for extragenital testing for chlamydia and gonorrhea. US Food and Drug Administration. Published May 23, 2019. Accessed July 28, 2021. <https://www.fda.gov/news-events/press-announcements/fda-clears-first-diagnostic-tests-extragenital-testing-chlamydia-and-gonorrhea>
19. Cantor A, Dana T, Griffen JC, et al. *Screening for Chlamydial and Gonococcal Infections: A Systematic Review Update for the US Preventive Services Task Force*. Evidence Synthesis No. 206. Agency for Healthcare Research and Quality; 2021. AHRQ publication 21-05275-EF-1.
20. St Cyr S, Barbee L, Workowski KA, et al. Update to CDC's treatment guidelines for gonococcal infection, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(50):1911-1916. Medline:33332296 doi:10.15585/mmwr.mm6950a6
21. Barrow RY, Ahmed F, Bolan GA, Workowski KA. Recommendations for providing quality sexually transmitted diseases clinical services, 2020. *MMWR Recomm Rep*. 2020;68(5):1-20. Medline:31899459 doi:10.15585/mmwr.rr6805a1
22. Krist AH, Davidson KW, Mangione CM, et al; US Preventive Services Task Force. Screening for hepatitis B virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. *JAMA*. 2020;324(23):2415-2422. Medline:33320230 doi:10.1001/jama.2020.22980
23. Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. *JAMA*. 2019;322(4):349-354. Medline:31334800 doi:10.1001/jama.2019.9365
24. Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. *JAMA*. 2020;323(10):970-975. Medline:32119076 doi:10.1001/jama.2020.1123
25. Bibbins-Domingo K, Grossman DC, Curry SJ, et al; US Preventive Services Task Force. Serologic screening for genital herpes infection: US Preventive Services Task Force recommendation statement. *JAMA*. 2016;316(23):2525-2530. Medline:27997659 doi:10.1001/jama.2016.16776
26. Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Screening for HIV infection: US Preventive Services Task Force recommendation statement. *JAMA*. 2019;321(23):2326-2336. Medline:31184701 doi:10.1001/jama.2019.6587

27. Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement. *JAMA*. 2019;321(22):2203-2213. Medline:31184747 doi:10.1001/jama.2019.6390
28. Bibbins-Domingo K, Grossman DC, Curry SJ, et al; US Preventive Services Task Force (USPSTF). Screening for syphilis infection in nonpregnant adults and adolescents: US Preventive Services Task Force recommendation statement. *JAMA*. 2016;315(21):2321-2327. Medline:27272583 doi:10.1001/jama.2016.5824
29. Curry SJ, Krist AH, Owens DK, et al; US Preventive Services Task Force. Screening for syphilis infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. *JAMA*. 2018;320(9):911-917. Medline:30193283 doi:10.1001/jama.2018.11785
30. Krist AH, Davidson KW, Mangione CM, et al; US Preventive Services Task Force. Behavioral counseling interventions to prevent sexually transmitted infections: US Preventive Services Task Force recommendation statement. *JAMA*. 2020;324(7):674-681. Medline:32809008 doi:10.1001/jama.2020.13095
31. Tao G, Irwin KL. Receipt of HIV and STD testing services during routine general medical or gynecological examinations: variations by patient sexual risk behaviors. *Sex Transm Dis*. 2008;35(2):167-171. Medline:18090177 doi:10.1097/OLQ.0b013e3181585be5
32. Cantor A, Dana T, Griffen JC, et al. Screening for chlamydial and gonococcal infections: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA*. Published September 14, 2021. doi:10.1001/jama.2021.10577
33. LeFevre ML; US Preventive Services Task Force. Screening for chlamydia and gonorrhea: US Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2014;161(12):902-910. Medline:25243785 doi:10.7326/M14-1981
34. Falasinnu T, Gilbert M, Gustafson P, Shoveller J. Deriving and validating a risk estimation tool for screening asymptomatic chlamydia and gonorrhea. *Sex Transm Dis*. 2014;41(12):706-712. Medline:25581805 doi:10.1097/OLQ.0000000000000205
35. Falasinnu T, Gilbert M, Gustafson P, Shoveller J. A validation study of a clinical prediction rule for screening asymptomatic chlamydia and gonorrhoea infections among heterosexuals in British Columbia. *Sex Transm Infect*. 2016;92(1):12-18. Medline:25933609 doi:10.1136/sextrans-2014-051992
36. Falasinnu T, Gilbert M, Gustafson P, Shoveller J. An assessment of population-based screening guidelines versus clinical prediction rules for chlamydia and gonorrhea case finding. *Prev Med*. 2016;89:51-56. Medline:27143496 doi:10.1016/j.ypmed.2016.04.001
37. Javanbakht M, Westmoreland D, Gorbach P. Factors associated with pharyngeal gonorrhea in young people: implications for prevention. *Sex Transm Dis*. 2018;45(9):588-593. Medline:29485543 doi:10.1097/OLQ.00000000000000822
38. Lavoué V, Morcel K, Voltzenlogel MC, et al. Scoring system avoids *Chlamydia trachomatis* overscreening in women seeking surgical abortions. *Sex Transm Dis*. 2014;41(8):470-474. Medline:25013973 doi:10.1097/OLQ.0000000000000153
39. Miller WC, Hoffman IF, Owen-O'Dowd J, et al. Selective screening for chlamydial infection: which criteria to use? *Am J Prev Med*. 2000;18(2):115-122. Medline:10698241 doi:10.1016/S0749-3797(99)00146-4

40. Berry L, Stanley B. Comparison of self-collected meatal swabs with urine specimens for the diagnosis of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in men. *J Med Microbiol.* 2017;66(2):134-136. Medline:28068218 doi:10.1099/jmm.0.000428
41. Fang J, Husman C, DeSilva L, Chang R, Peralta L. Evaluation of self-collected vaginal swab, first void urine, and endocervical swab specimens for the detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in adolescent females. *J Pediatr Adolesc Gynecol.* 2008;21(6):355-360. Medline:19064231 doi:10.1016/j.jpag.2008.03.010
42. Nye MB, Osiecki J, Lewinski M, et al. Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* with the cobas CT/NG v2.0 test: performance compared with the BD ProbeTec CT Qx and GC Qx amplified DNA and Aptima AC2 assays. *Sex Transm Infect.* 2019;95(2):87-93. Medline:30126947 doi:10.1136/sextrans-2018-053545
43. Schachter J, McCormack WM, Chernesky MA, et al. Vaginal swabs are appropriate specimens for diagnosis of genital tract infection with *Chlamydia trachomatis*. *J Clin Microbiol.* 2003;41(8):3784-3789. Medline:12904390 doi:10.1128/JCM.41.8.3784-3789.2003
44. Schoeman SA, Stewart CM, Booth RA, Smith SD, Wilcox MH, Wilson JD. Assessment of best single sample for finding chlamydia in women with and without symptoms: a diagnostic test study. *BMJ.* 2012;345:e8013. Medline:23236032 doi:10.1136/bmj.e8013
45. Shrier LA, Dean D, Klein E, Harter K, Rice PA. Limitations of screening tests for the detection of *Chlamydia trachomatis* in asymptomatic adolescent and young adult women. *Am J Obstet Gynecol.* 2004;190(3):654-662. Medline:15041995 doi:10.1016/j.ajog.2003.09.063
46. Skidmore S, Kaye M, Bayliss D, Devendra S. Validation of COBAS Taqman CT for the detection of *Chlamydia trachomatis* in vulvo-vaginal swabs. *Sex Transm Infect.* 2008;84(4):277-278. Medline:18305120 doi:10.1136/sti.2007.029587
47. Stewart CM, Schoeman SA, Booth RA, Smith SD, Wilcox MH, Wilson JD. Assessment of self taken swabs versus clinician taken swab cultures for diagnosing gonorrhoea in women: single centre, diagnostic accuracy study. *BMJ.* 2012;345:e8107. Medline:23236033 doi:10.1136/bmj.e8107
48. Sultan B, White JA, Fish R, et al. The "3 in 1" study: pooling self-taken pharyngeal, urethral, and rectal samples into a single sample for analysis for detection of *Neisseria gonorrhoeae* and *Chlamydia trachomatis* in men who have sex with men. *J Clin Microbiol.* 2016;54(3):650-656. Medline:26719439 doi:10.1128/JCM.02460-15
49. Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for *Chlamydia trachomatis* to prevent pelvic inflammatory disease: the POPI (Prevention Of Pelvic Infection) trial.. 2010;340:c1642. Medline:20378636 doi:10.1136/bmj.c1642</jrn>
50. Ostergaard L, Andersen B, Møller JK, Olesen F. Home sampling versus conventional swab sampling for screening of *Chlamydia trachomatis* in women: a cluster-randomized 1-year follow-up study. *Clin Infect Dis.* 2000;31(4):951-957. Medline:11049776 doi:10.1086/318139
51. Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. *N Engl J Med.* 1996;334(21):1362-1366. Medline:8614421 doi:10.1056/NEJM199605233342103
52. Hocking JS, Temple-Smith M, Guy R, et al; ACCEPt Consortium. Population effectiveness of opportunistic chlamydia testing in primary care in Australia: a cluster-randomised controlled trial. *Lancet.* 2018;392(10156):1413-1422. Medline:30343857 doi:10.1016/S0140-6736(18)31816-6

53. US Preventive Services Task Force. Screening for chlamydial infection—including ocular prophylaxis in newborns. In: *Guide to Clinical Preventive Services: Report of the US Preventive Services Task Force*. 2nd ed. US Department of Health and Human Services; 1996.
54. Ryan GM Jr, Abdella TN, McNeeley SG, Baselski VS, Drummond DE. *Chlamydia trachomatis* infection in pregnancy and effect of treatment on outcome. *Am J Obstet Gynecol*. 1990;162(1):34-39. Medline:2301514 doi:10.1016/0002-9378(90)90815-O
55. US Preventive Services Task Force. Screening for gonorrhea—including ocular prophylaxis in newborns. In: *Guide to Clinical Preventive Services: Report of the US Preventive Services Task Force*. 2nd ed. US Department of Health and Human Services; 1996.
56. Chlamydia, gonorrhea, and syphilis. American College of Obstetricians and Gynecologists. Published January 2021. Accessed July 28, 2021. <https://www.acog.org/womens-health/faqs/chlamydia-gonorrhea-and-syphilis>
57. Routine tests during pregnancy. American College of Obstetricians and Gynecologists. Updated July 2021. Accessed July 29, 2021. <https://www.acog.org/womens-health/faqs/routine-tests-during-pregnancy>
58. Clinical Preventive Service Recommendation: sexually transmitted infections. American Academy of Family Physicians. Accessed July 28, 2021. <https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/stis.html>
59. Committee on Adolescence; Society for Adolescent Health and Medicine. Screening for nonviral sexually transmitted infections in adolescents and young adults. *Pediatrics*. 2014;134(1):e302-e311. Medline:24982099 doi:10.1542/peds.2014-1024

Table. Summary of USPSTF Rationale

Rationale	Assessment
Detection	<ul style="list-style-type: none"> <li>Convincing evidence that screening tests can accurately detect chlamydia and gonorrhea in asymptomatic women and men.</li> </ul>
Benefits of early detection and intervention and treatment	<ul style="list-style-type: none"> <li>Adequate direct evidence that screening for chlamydia in sexually active women at increased risk reduces infection complications, with a moderate magnitude of benefit.</li> <li>Adequate evidence that screening for gonorrhea in sexually active women at increased risk results in a moderate magnitude of benefit, based on the large proportion of cases that are asymptomatic, the effectiveness of antibiotic treatment to reduce infections, and the high morbidity associated with untreated infections.</li> </ul>
Harms of early detection and intervention and treatment	<ul style="list-style-type: none"> <li>Adequate evidence to bound the harms of screening for chlamydia and gonorrhea in both women and men as small to none, based on the nature of the interventions, low likelihood of serious harms, and available information from studies reporting few harms. When direct evidence is limited, absent, or restricted to select populations or clinical scenarios, the USPSTF may place conceptual upper or lower bounds on the magnitude of benefit or harms.</li> </ul>

USPSTF assessment	<ul style="list-style-type: none"><li>• Moderate certainty that screening for chlamydia in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection has moderate net benefit.</li><li>• Moderate certainty that screening for gonorrhea in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection has moderate net benefit.</li><li>• Insufficient evidence to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men. Evidence is lacking that screening men reduces infection complications and transmission or acquisition of either disease or HIV.</li></ul>
-------------------	---

**Abbreviation:** USPSTF, US Preventive Services Task Force.